



A TALE OF TWO STUDIES:A COMPARISON OF
ECONOMIC DATA FROM A CLINICAL TRIAL TO
A CROSS-SECTIONAL DATABASE
Crawford B, Evans C
Mapi Values, Boston, MA, USA
When economic evaluations are conducted alongside 
clinical trials estimates of resource utilization (RU) are
likely to be inaccurate. This problem arises due to pres-
ence of protocol-mandated visits and forced compliance.
It is rare to ﬁnd two databases that may be compared to
determine the scale of this problem. OBJECTIVE: 1) To
compare the resource utilization associated with rheuma-
toid arthritis from a clinical trial database to a cross-
sectional database, and 2) to understand advantages 
and disadvantages of using each database in economic
analyses. METHODS: In this novel study, two databases
were examined: one a pragmatic, cross-sectional 
database (CSD: with 6-month retrospective recall of RU)
of rheumatoid arthritis patients (RA) and the other a 
database from a phase III clinical trial program (CTD) in
RA matched on several demographic variables. Subjects
were age/gender matched to control for differences in the
database populations. Hospitalizations, GP and special-
ist visits were compared between the databases.
RESULTS: When the CTD is examined for just protocol
visits, a total of 8 specialist consultations were recorded.
When the CTD is examined for non-protocol visits, few
additional visits are recorded: 0.12 GP visits, 0.11 spe-
cialist consultations, and 0.01 hospitalizations. The addi-
tion of the non-protocol visits to the protocol total visits
increase RU to 8.12 GP visits and 8.11 specialist consul-
tations. Based on data from the CSD, over a 6-month time
frame, randomly matched on age and gender, an average
of 2.1 GP visits, 2.21 specialist consultations, and 1.3
hospitalizations were reported by patients. CONCLU-
SIONS: The inclusion of protocol-mandated visits 
substantially overstates true RU while their omission
understates thereby leaving researchers in a quandary.
The use of CTDs for modeling purposes raises the issues
of generalizability and accuracy and suggests that natu-
ralistic rather than piggyback trials should be used for PE
evaluations.
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THE PARAMETRIC BOOTSTRAP: RECONCILING
PARAMETRIC AND NON PARAMETRIC
METHODS IN THE ESTIMATION OF




OBJECTIVES: Many authors have addressed the issue 
of handling uncertainty in stochastic cost-effectiveness
analyses. They generally oppose parametric (Fieller’s
theorem, conﬁdence box or ellipse . . .) and non para-
metric (bootstrap) methods. The parametric bootstrap is
at the bridge of these two families of methods. Paramet-
ric bootstrap was used to assess conﬁdence interval of the
incremental cost-effectiveness ratio (ICER) of a drug used
in the treatment of post-infarction patients and the esti-
mated CI was compared to that provided by non para-
metric bootstrap. METHODS: Data were derived from a
placebo-controlled clinical trial on 1749 patients included
just after MI and followed over 4 years. Patient-level costs
were computed to reﬂect the US Health care system. The
parametric bootstrap was based on the assumption that
the incremental costs and effects differentials follow a
normal bivariate distribution. Five thousand re-samples
were made from the normal bivariate density function.
The non parametric bootstrap was based on 5000 re-
samples from the original sample. Mean ICER estimates
and percentiles CI are presented for both techniques.
RESULTS: The mean ICER from the original sample 
was estimated to US$2574 per life-year saved. The para-
metric bootstrap provided an estimated ICER of
US$2726/LYS and the 95% CI was [1164; 5210]. From
the non parametric bootstrap, the ICER estimate was
US$3419/LYS and the 95% CI was [1660; 5254]. CON-
CLUSIONS: The parametric bootstrap provided a CI,
which seemed to be in accordance with that of the non
parametric bootstrap. It still needs to be compared to
other parametric and non parametric methods, particu-
larly in terms of coverage properties. It can be a useful
tool, as it allows assumptions on the ICER joint distribu-
tion, without implying speciﬁc textbook formulae.
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THE IMPLICATIONS OF COMBINING
HETEROGENEOUS PATIENT POPULATIONS IN
META-ANALYSES
Boler A, Howard P
Heron Evidence Development, Letchworth, Hertfordshire,
United Kingdom
Systematic reviews and meta-analyses attempt to 
minimise the biases from individual trials but can, on
some occasions, miss or conceal beneﬁcial treatment
effects when trials, with varying patient populations, are
analysed together. OBJECTIVE: To investigate the effect
of ‘splitting’ diverse patient populations using part of a
published meta-analysis of randomised controlled trials
for the prevention of vascular events in high-risk patients.
METHODS: Our study re-evaluated a section of results
of a well-known meta-analysis of RCTs for the preven-
tion of vascular events. The original review (ATC) esti-
mated the combined treatment effect of dipyridamole plus
aspirin (DP + ASA) compared to aspirin (ASA) alone
using data from 25 clinical trials for all patients, regard-
less of their vascular morbidity proﬁle. Patients who had
previously experienced an MI, TIA/stroke, CABG, coro-
nary angioplasty, intermittent claudication, peripheral
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grafts, angioplasty, haemodialysis and diabetes were
“lumped” together for analysis. We re-evaluated the data
by meta-analysing sub-groups of trials according to the
risk factor of the patient population (where there was
more than one trial for the risk factor). RESULTS: The
Relative Risk Reductions with [95% CI] for DP + ASA
compared to ASA alone for all types of patients was cal-
culated to be 5% [-5 to 15%]. However the RRRs were
diverse when trial patient populations were split for
analysis. RRRs ranged from 15% [4% to 26%] for
patients with previous Stroke/TIA to -19% [-62% to
12%] for patients who had had CABG previous to enter-
ing the study. CONCLUSIONS: The usefulness of the
ATC’s summary statistics in decision-making for speciﬁc
patient populations is limited, due to heterogeneous
patient populations being combined together. In particu-
lar, our sub-group analysis revealed a statistically signiﬁ-
cant RRR in vascular events for patients treated with DP
+ ASA compared to ASA amongst patients with previous
TIA/stroke.
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STOCHASTIC ANALYSIS OF AN RANDOMIZED
CONTROLLED TRIAL IN REHABILITATION OF
LOW BACK PATIENTS: REPRESENTATION OF
UNCERTAINTY WHEN EFFECT DIFFERENCE IS
SMALL
Schweikert B1, Jacobi E1, Knab J2, Leidl R1
1University of Ulm, Ulm, Germany; 2University Hospital of
Essen, Essen, Germany
OBJECTIVE: Various representations of uncertainty in
cost effectiveness analysis alongside a randomized trial
have been suggested. Due to its informational richness the
cost acceptability curve has been favored. Alternative rep-
resentations of uncertainty are conﬁdence intervals and
bootstrap distribution in the c/e plane. If the difference in
effects is small different problems arise with either of the
methods. Aspects of using the different presentations of
uncertainty for decision making are discussed for the
study example. METHODS: Methods compared included
cost-effectiveness acceptability curve bootstrap conﬁ-
dence intervals and bootstrap scatter plots focusing on
their user-friendliness, informational richness and guid-
ance for decision making. Data came from an economic
evaluation in the rehabilitation of low back patients that
has been performed in two German rehabilitation centers.
Treatment in the standard arm consisted of a multimodal
program including physiotherapy and educational mea-
sures. The experimental group received additional psy-
chological treatment. RESULTS: The cost effectiveness
acceptability curve intersecting at 0.61 showed a small
slope. The bootstrap conﬁdence interval ranged from €1.4
million to €-20.000 covering points in all quadrants.
61% of the bootstrap replicates where in the southeast
quadrant indicating dominance. CONCLUSIONS: Sug-
gestions are made for further discussion of using uncer-
tain results for decision making as a conservative rule for
a risk-neutral decision maker, it is suggested that a 50%
probability of the intervention being dominant (as found
in the study) may not be used to reject it on economic
grounds.
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ASTHMA TREATMENT PREFERENCE STUDY—
A CONJOINT ANALYSIS OF PREFERRED DRUG
TREATMENTS
Berggren F1, Ställberg B2,Tornling G1, Fält K3,Andersson S1,
Karlsson G1, Johansson G4
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OBJECTIVE: Assessment of patient preferences for
attributes of asthma treatments. METHODS: Two
hundred ninety-eight patients, aged 18–60, from 15
centres in Sweden completed a questionnaire concern-
ing their asthma and ranked 18 alternative treatments
using conjoint analysis. Patients were treated with either
inhaled corticosteroids (ICS) or short acting bron-
chodilator alone (n = 123) or ICS and long acting bron-
chodilator (separate inhalers n = 87, combination inhaler
n = 88). Attributes analysed were: maintenance treatment,
additional reliever, time to onset and duration of reliever,
number of symptom-free days (SFD) per month, and out-
of-pocket cost per month. RESULTS: Conjoint analysis
showed that the most important aspect of treatment was
SFD. Forty percent of the patients had 15 or less SFD per
month. Eighty-ﬁve percent of the patients preferred
another treatment than their current treatment. Treat-
ment preferences were heterogeneous and in 78% not
covered by current treatment guidelines. One of two
patients preferred a combination inhaler to separate
inhalers, and three of four patients a reliever that is both
rapid- and long-acting. The most preferred treatment was
a combination inhaler for maintenance and reliever use.
On average, the patients were willing to pay SEK 328
(USD $36), additionally to their current expenditure, per
month for the change to the preferred treatment. CON-
CLUSION: Symptom-free days were the most important
attribute in asthma treatment. Patients were willing to
pay for a switch to their preferred treatment. The most
favoured treatments were a reliever therapy that is both
rapid- and long acting and a combination inhaler for both
maintenance and as needed use.
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TRANSFORMING THE UNIFIED PARKINSON’S
DISEASE RATING SCALE INTO A UTILITY
SCALE
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